Discover and understand unmet needs in the ADHD market

The current global ADHD market is worth $2.7billion and is expected to reach $3.3billion by 2015, driven primarily by the launch of pipeline drugs and the continued growth of Strattera.

Innovation is key - manufacturers can no longer expect significant returns on standard extended release formulations. The current pipeline offers drugs with novel delivery mechanisms; improved durations of action and anti-abuse profiles, which will help differentiate these pipeline drugs from the current established ADHD therapies.

Although ADHD drugs have demonstrated significant efficacy in improving the three main symptoms of ADHD - inattention, hyperactivity and impulsivity - none have shown efficacy in treating the cognitive deficits of ADHD.

Find out more in Datamonitor's latest report:

Pipeline Insight: ADHD - Shire Driving Diversity in ADHD

Detailed analysis of ADHD drugs in late-stage clinical development, including clinical trial results, key issues and commercial challenges. Assessment and forecasts supported by opinion leader comments, plus Datamonitor's strategic recommendations.

This essential report includes:

Ø      Overview of the epidemiology, diagnosis and management of ADHD across the seven major pharmaceutical markets; the US, Japan, France, Germany, Italy, Spain and the UK

Ø      Examination of the ADHD pipeline with in-depth clinical and commercial profiles of late-stage candidates, incorporating Datamonitor opinion

Ø      Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2015

Ø      Insight and commentary from qualitative interviews with ADHD opinion leaders in the US and Europe

What you will find out: 

Ø      Understand unmet needs in the ADHD market based on opinion leader comments regarding both currently marketed and pipeline products

Ø      Benchmark key late-stage ADHD compounds against current market leaders

Ø      Assess the global sales forecasts of late-stage pipeline drugs for ADHD and examine their clinical and commercial potential

Product Details

Published: Jun-05         Code: DMHC2093         Price: $11400

To purchase this report clisk title below:

Pipeline Insight: ADHD - Shire Driving Diversity in ADHD

This report comes with a PowerPoint slide pack and Excel Data pack

To order these reports contact peter.barfoot@bioportfolio.com or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you.

You can also order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html